dosing regimens for administration of an anti-cd25 adc

摘要

the present disclosure refers to new dosage regimens for the treatment of pathological conditions, such as cancer, with drug antibody conjugates (adcs). in particular, the present disclosure relates to new dosage regimens for the administration of adducts that bind to cd25 (cd25-adcs).